ReviewCellular and molecular life sciences : CMLS2021
Immune responses and therapeutic options in psoriasis.
Review in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 70 citations in OpenAlex.
- Multiomics analysis reveals dermokine as a regulator of keratinocyte differentiation and adhesion.JCI insight · 2026Article
- Design, Development, and Characterization of a Tannic Acid-loaded Transfersomal Gel for Psoriatic Skin.Pharmaceutical research · 2026Article
- Zingiber officinale essential oil mitigates psoriasis-like skin inflammation by modulating inflammatory and proliferative responses: in-silico, in-vitro, and in-vivo studies.Inflammopharmacology · 2026Article
- Review
- Mitochondria-targeted nanozyme system for psoriasis treatment.Journal of nanobiotechnology · 2026Article
- Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Observational
- Integrated transcriptomic and tissue-validation analyses identify palmitoylation-associated biomarkers linked to sphingolipid metabolism and immune remodeling in psoriasis.Frontiers in immunology · 2026Article
- Dermal mesenchymal stem cells promote angiogenesis in HMEC-1 via activation of the angiopoietin 1/Tie2 pathway in psoriasis.Frontiers in cell and developmental biology · 2026Article
- Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report.Frontiers in medicine · 2026Article
- Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis.Therapeutic advances in neurological disorders · 2026Article
- TGM1 as a novel signature gene in psoriasis identified by integrative bioinformatics and experimental validation.Molecular medicine reports · 2026Article
- The Therapeutic Potential of Extracellular Vesicles in Psoriasis Treatment: Mechanisms, Applications, and Prospects.International journal of molecular sciences · 2025Review
- Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases.Cell & bioscience · 2025Review
- Microbiome-Based Products: Therapeutic Potential for Inflammatory Skin Diseases.International journal of molecular sciences · 2025Review
- LncRNA LINC01026 Is Overexpressed in Psoriasis and Enhances Keratinocyte Cell Cycle Progression by Regulating the Ets Homologous Factor (EHF).Journal of cellular and molecular medicine · 2025Article
- Sinhyotaklisan as a Potential Therapeutic for Psoriasis: Network Pharmacology and Experimental Validation.International journal of molecular sciences · 2025Article
- Combination Effects of Aminolevulinic Acid and Mycophenolic Acid on Hacat Cell Proliferation and Inhibition of Inosine Monophosphate Dehydrogenase.Molecules (Basel, Switzerland) · 2025Article
- Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.Non-coding RNA · 2025Review
- Prevalence and clinical features of interstitial lung disease in patients with psoriasis.BMC pulmonary medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Psoriasis is a chronic inflammatory disease of the skin that affects about 2-3% of the population and greatly impairs the quality of life of affected individuals. Psoriatic skin is characterized by excessive proliferation and aberrant differentiation of keratinocytes, as well as redness caused by increased dilation of the dermal blood vessels and infiltration of immune cells. Although the pathogenesis of psoriasis has not yet been completely elucidated, it is generally believed to arise from a complex interplay between hyperproliferating keratinocytes and infiltrating, activated immune cells. So far, the exact triggers that elicit this disease are still enigmatic, yet, it is clear that genetic predisposition significantly contributes to the development of psoriasis. In this review, we summarize current knowledge of important cellular and molecular mechanisms driving the initiation and amplification stages of psoriasis development, with a particular focus on cytokines and emerging evidence illustrating keratinocyte-intrinsic defects as key drivers of inflammation. We also discuss mouse models that have contributed to a better understanding of psoriasis pathogenesis and the preclinical development of novel therapeutics, including monoclonal antibodies against specific cytokines or cytokine receptors that have revolutionized the treatment of psoriasis. Future perspectives that may have the potential to push basic research and open up new avenues for therapeutic intervention are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.